Results 91 to 100 of about 1,005 (173)

Eficacia y seguridad del Pitolisant en el tratamiento de la narcolepsia: revisión sistemática

Título: Eficacia y seguridad del Pitolisant en el tratamiento de la narcolepsia: revisión sistemática. Objetivo: Determinar la eficacia y seguridad del pitolisant en el tratamiento de la narcolepsia.
Orbe Orbe, Willian Isael
core  

Advances in Non-CPAP Management of Obstructive Sleep Apnea: Spotlight on Pharmacological Therapies. [PDF]

J Pers Med
Siciliano M, de Scisciolo M, Fratini A, Sottani C, Giordani F, Brunetti V.   +5 more
europepmc   +1 more source

Clinical pearls for the treatment of narcolepsy. [PDF]

Ment Health Clin
Bulloch MN, Geyer JD.
europepmc   +1 more source

Narcolepsy as an immune-associated hypothalamic encephalopathy: orexin dysfunction and implications for precision sleep medicine. [PDF]

Front Psychiatry
Arias-Carrión O, Ortega-Robles E, Romano P, Pineda C.   +3 more
europepmc   +1 more source

Editorial: Non-invasive methods in drug metabolism and transport: insights from biological samples to oral administration. [PDF]

Front Pharmacol
Wróblewski K, Zheng Y, Yue X.
europepmc   +1 more source

Simultaneous inhibition of cholinesterase and antagonism of histamine H3 receptors alleviates cognitive deficits and mitigates apoptosis in scopolamine-induced amnesia in mice. [PDF]

Front Behav Neurosci
Ebdah W, Thomas SD, Eissa N, Jayaprakash P, Łażewska D, Kieć-Kononowicz K, Sadek B.   +6 more
europepmc   +1 more source

Comparaison du profil de sécurité du pitolisant et du solriamfétol : revue systématique et méta-analyse

Excessive daytime sleepiness is a symptom found in patients with narcolepsy or sleep apnoea-hypopnoea syndrome (SAHOS). The first-line drug treatments for excessive daytime sleepiness, pitolisant and solriamfetol, may have different safety profiles.
Toth, Rémi
core  

Drug Interactions With Excessive Daytime Sleepiness Treatments. [PDF]

J Pharm Technol
Thomas SV, Malesker MA, Hilleman DE, Dewan NA.   +3 more
europepmc   +1 more source

Histamine H3 Receptor Antagonists Influence the Directional Growth of Type II Spiral Ganglion Neurites Within the Developing Cochlea of C57BL/6 Mice. [PDF]

Neurochem Res
Kong L, Olze H, Szczepek AJ.
europepmc   +1 more source

Preclinical Evidence for Antidepressant-like Effects of Histamine H3 Receptor Modulation: A Systematic Review and Meta-Analysis. [PDF]

Life (Basel)
Pullano I, Iazzolino AM, Landi S, Vignapiano A, Monaco F, Steardo L.   +5 more
europepmc   +1 more source